Plain-English translation of NCT06269432 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After an ischemic stroke, doctors typically prescribe aspirin to prevent another one. However, about one-third of patients don't respond well to aspirin or similar medications, even at the right dose. This trial tests whether a simple blood test that measures how your blood clots can help your doctor pick the medication that works best for you personally, rather than giving everyone the same drug.
Many stroke survivors keep having strokes even while taking standard blood-thinning medications because their blood clots despite the treatment. This trial aims to solve that problem by using blood testing to match each patient with the medication most likely to work for them.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group receives personalized medication selection based on a blood clotting test, while the other group takes a standard aspirin dose daily. You'll have blood drawn to measure how your blood clots and guide your treatment. The study will follow you over time to see if the personalized approach helps prevent another stroke better than the standard approach.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China